title: Murine model of primary intraocular lymphoma.
abstract: OBJECTIVE
  Primary intraocular lymphoma (PIOL) is a subtype of central nervous system lymphoma. Although this lymphoma is rare, its incidence has tripled in the past 15 years. Currently, the only available model is a murine metastatic malignant lymphoma that occurs after intraperitoneal inoculation of Rev-2-T-6 lymphoma cells into newborn syngeneic mice. The current study was conducted to develop a new experimental model for PIOL.
  
  
  METHODS
  Rev-2-T-6 cells (0.5 x 10(5) or 1.0 x 10(5)) were inoculated into the vitreous of adult BALB/c mice. Mice were monitored clinically every other day and under fundoscopic examination weekly. They were euthanatized on weeks 3, 5, 6, 7, or 8, after inoculation. All eyes were processed for histology. Immunohistochemistry was performed with an antibody (p14) specific for Rev-2-T-6 cells. Cytokine mRNA expression (IL-2, -4, -6, -10, and IFN-gamma and CC chemokine receptor-1 [CCR1]) was assayed in the lymphoma cells by microdissection and RT-PCR. IL-10 and -6 levels in the vitreous were measured by ELISA.
  
  
  RESULTS
  Within 2 to 4 weeks, tumor cells from the vitreous migrate through the retina and gather between the RPE cell and retina. Rarely (>2 months after inoculation), Rev-2-T-6 cells may break through the RPE and infiltrate the choroid and sclera. Tumor localization was confirmed by immunohistochemistry. The intraocular lymphoma cells produce high levels of IL-10, IFN-gamma, and CCR1 transcripts. A high level of IL-10 was detected in the vitreous inoculated with Rev-2-T-6 cells.
  
  
  CONCLUSIONS
  The data suggest that RPE cells constitute a barrier to the spread of intraocular lymphoma. Intravitreal injection of Rev-2-T-6 cells is a novel model of PIOL in immune-competent hosts that will aid in understanding the molecular mechanisms of the disease.
authors.affiliation: Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892-1857, USA. chanc@nei.nih.gov
authors.forename: Chi-Chao
authors.initials: CC
authors.lastname: Chan
authors.forename: Maria
authors.initials: M
authors.lastname: Fischette
authors.forename: DeFen
authors.initials: D
authors.lastname: Shen
authors.forename: Sankaranarayana P
authors.initials: SP
authors.lastname: Mahesh
authors.forename: Robert B
authors.initials: RB
authors.lastname: Nussenblatt
authors.forename: Jacob
authors.initials: J
authors.lastname: Hochman
mesh_terms: D000818:Animals; D016207:Cytokines / Q000235:genetics; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D005134:Eye Neoplasms / Q000378:metabolism / Q000473:pathology*; D016399:Lymphoma, T-Cell / Q000378:metabolism / Q000473:pathology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D010857:Pigment Epithelium of Eye / Q000473:pathology; D012333:RNA, Messenger / Q000378:metabolism; D054389:Receptors, CCR1; D019707:Receptors, Chemokine / Q000378:metabolism; D019572:Retinal Neoplasms / Q000378:metabolism / Q000473:pathology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014407:Tumor Cells, Cultured; D014822:Vitreous Body / Q000378:metabolism / Q000473:pathology*
chemical_list: C515301:Ccr1 protein, mouse; D016207:Cytokines; D012333:RNA, Messenger; D054389:Receptors, CCR1; D019707:Receptors, Chemokine